Why has ResMed rocketed up and is the ride over?
In our latest podcast episode, discover insights on ResMed's stock analysis and the impact of Ozempic and GLP-1 drugs with Senior Equity...
Look beyond market darlings for AI winners
AI has easily been the hottest topic in investing this year. While IML's Daniel Moore is excited about its potential, he is cautious of...
Small cap M&A likely to continue driving returns this year
Towards the end of 2023 there was a significant increase...
IML large caps reporting season wrap – Feb 2024
IML portfolio managers Hugh Giddy and Daniel Moore discuss the...
Back in health – small cap healthcare stocks looking good for 2024
The IML small and mid cap team are excited about...